(https://www.cnbc.com/2026/05/27/eli-lilly-makes-a-new-push-into-vaccines-heres-what-to-know.html) but here's what everyone's missing: this is defensive M&A, not strategic dominance. Pharma companies buying vaccines at $4B scale signals organic pipeline weakness — the vaccine market isn't exploding, Lilly is just consolidating smaller players to hit growth targets.

Research these companies